$Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis$

Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis

This article conducts a meta-analysis to evaluate the safety and efficacy of PD-1/PD-L1 inhibitors in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). A total of 63 papers were initially retrieved, and eight clinical studies were collected. The estimated effect of ORR was...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhang Jiawen, Xu Lei, Sun Caifeng, Huang Zonghua, Ma Ji, Wang Liang
Format:	Article
Language:	English
Published:	De Gruyter 2025-08-01
Series:	Open Life Sciences
Subjects:	pd-1/pd-l1 blockade immune checkpoint molecule relapsed/refractory diffuse large b-cell lymphoma treatment meta-analysis
Online Access:	https://doi.org/10.1515/biol-2025-1129
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

Impact of Hematopoietic Stem Cell Transplantation on PD-1 Blockade Efficacy in Relapsed/Refractory Hodgkin’s Lymphoma
by: Filomena Emanuela Laddaga, et al.
Published: (2025-04-01)

Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Shiliang Ge, et al.
Published: (2025-02-01)

Efficacy and safety of PD-1/PD-L1 inhibitors for natural killer/T-cell lymphoma: a single-arm meta-analysis
by: Jiao Yang, et al.
Published: (2025-03-01)

Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia
by: Hui-Sheng Zhou, et al.
Published: (2025-04-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade
by: Yujun Bao, et al.
Published: (2024-12-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
by: Peng Gao, et al.
Published: (2025-08-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01)

Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
by: Green Hong, et al.
Published: (2025-04-01)

Production of Antibodies Binding Murine Nuclear PD-L1
by: Valentina Kostenko, et al.
Published: (2024-04-01)

Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients
by: Yingxia Lan, et al.
Published: (2025-06-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

PD-L1 as a Potential Target in Cancer Therapy (Review)
by: N. N. Andrusova, et al.
Published: (2021-02-01)

Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
by: Tetsuichi Kansha, et al.
Published: (2025-07-01)

Platelet‐to‐Neutrophil Ratio: A Novel Prognostic Indicator for Anti‐PD‐1‐Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors
by: Yuting Pan, et al.
Published: (2025-06-01)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Expression of inhibitory receptors PD-1, CTLA-4, and Tim-3 by peripheral T cells during pregnancy
by: E. A. Smetanenko, et al.
Published: (2022-10-01)

The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study
by: Rosaria De Filippi, et al.
Published: (2025-12-01)

Galectin-9 and Tim-3 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti-PD-1 blockade
by: Charlotte N. Hill, et al.
Published: (2025-07-01)

Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model
by: Muhammad Zaeem Noman, et al.
Published: (2025-12-01)

Evaluation of polymorphism in BCL-2, PD-1, and PD-L1 genes in myelodysplastic neoplasms
by: Bartłomiej Kuszczak, et al.
Published: (2025-01-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma
by: Yaoyao Jing, et al.
Published: (2025-07-01)

Development of a Mammalian Cell Line for Stable Production of Anti-PD-1
by: Erika Csató-Kovács, et al.
Published: (2024-10-01)

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study
by: Baoyue Pan, et al.
Published: (2025-06-01)

Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1
by: Barry D. Hock, et al.
Published: (2025-05-01)

High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils
by: Alexander Emmanuelli, et al.
Published: (2024-12-01)

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
by: Qian Zhu, et al.
Published: (2025-04-01)

Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01)

TRPV1 inhibition sensitizes tumors to PD-1 blockade by reversing resistance to CTL-mediated killing
by: Min Kyu Son, et al.
Published: (2025-07-01)

Association of Hepatitis-B virus infection status with survival and treatment response in non-small cell lung cancer patients on anti‐pd‐1/pd-l1 therapy
by: Eda Alp, et al.
Published: (2024-12-01)

Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model
by: Tomoatsu Ikeya, et al.
Published: (2025-07-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Immune Checkpoint Inhibitors in the Treatment of Lymphomas
by: KV Lepik
Published: (2018-10-01)

Relapsing polychondritis following PD-1 blockade diagnosed via 18F-FDG PET/CT and improved by steroid administration: a case report and literature review
by: Ruo-Wen Xu, et al.
Published: (2025-08-01)